Pipeline

ABL301

HomePipelineABL301

Publications

Lee S et al. ABL301, BBB-Crossing Trojan Horse Bispecific Antibody Specifically Targeting Aggregated a-synuclein for the Treatment of Parkinson’s Disease (PD). Keystone 2019

Download

ABL301

First-in & Best-in-Class BsAb Targeting Aggregated ɑ-Synuclein with BBB Penetrating Shuttle

Parkinson's Disease

Parkinson's Disease
Parkinson's Disease

ABL301 Overview

ABL301 Overview
ABL301 Overview

IGF1R as an Ideal BBB Shuttle Target

IGF1R is Highly Expressed in Brain Vessels

IGF1R is Highly Expressed in Brain Vessels
IGF1R is Highly Expressed in Brain Vessels

ABL301 Ameliorates Synucleinopathy by Two Different MOAs

ABL301 Ameliorates Synucleinopathy by Two Different MOAs
좌우스크롤 ABL301 Ameliorates Synucleinopathy by Two Different MOAs

Fully Optimized GrabodyTM B Demonstrates Superior BBB Penetrance

In Vitro GrabodyTM B Evolution
1. Affinity maturation
2. Half-life extension
3. Valency control
Fully Optimized GrabodyTM B Demonstrates Superior BBB Penetrance
좌우스크롤 Fully Optimized GrabodyTM B Demonstrates Superior BBB Penetranceb

Superb BBB Penetration Rate of Grabody™ B in Vivo

Superb BBB Penetration Rate of Grabody™ B in Vivo
Superb BBB Penetration Rate of Grabody™ B in Vivo

Anti-α-Synuclein Antibody Improved Pathophysiology in PD Animal Model

Anti-α-Synuclein Antibody Improved Pathophysiology in PD Animal Model
Anti-α-Synuclein Antibody Improved Pathophysiology in PD Animal Model

Monovalent Format is Better than Bivalent Format

Monovalent Format is Better than Bivalent Format
Monovalent Format is Better than Bivalent Format

Grabody™ B Can be Applied to Multiple CNS Indications

Grabody™ B Can be Applied to Multiple CNS Indications
좌우스크롤 Grabody™ B Can be Applied to Multiple CNS Indications